HSD17B12

Across TCGA pan-cancer cohorts, HSD17B12 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of HSD17B12’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where HSD17B12 RNA is repressed in tumor relative to normal tissue. In most cancer types HSD17B12 is over-expressed in tumor, although a few such as KIRC and THCA show the opposite, repressed pattern.

KIRC, THCA, and COAD are the cancer types where HSD17B12 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HSD17B12 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	−0.870	<.001	11	view →
THCA	All	All	−0.388	<.001	9	view →
COAD	Male	All	+0.763	<.001	8	view →
LUSC	All	All	−0.388	<.001	6	view →
KICH	All	All	−0.562	.006	4	view →
STAD	Male	All	+0.540	.001	4	view →
BRCA	Female	II,III,IV	−0.236	.001	4	view →
LUAD	All	All	−0.218	.008	4	view →
KIRP	Male	All	−0.525	.002	3	view →
HNSC	All	All	+0.303	.026	3	view →
READ	All	III,IV	+0.725	.015	2	view →
KIRP	Female	II,III,IV	+0.599	.033	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

HSD17B12–KIRC

Open the KIRC breakdown →